Clinical Trials

2,023 enrolled

Breast Neoplasms

NCT05411380 2022-11-04

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

73 enrolled

Breast Neoplasms

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

434 enrolled

Advanced Breast Cancer

NCT03966898 2021-06-02

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

426 enrolled

Advanced Breast Cancer

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

3,697 enrolled

Breast Neoplasms

NCT04236310 2020-01-22

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

37 enrolled

Breast Neoplasms

NCT04088110 2019-09-12

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

77 enrolled

Breast Diseases, Breast Neoplasms

NCT03024580 2019-08-15

MEGA

20 enrolled

Breast Neoplasms

NCT04023292 2019-07-17

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

185 enrolled

Breast Neoplasms

NCT03910712 2019-04-10

Pyrotinib

250 enrolled

Breast Diseases, Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

7 enrolled

Breast Neoplasms

NCT02910050 2017-12-22

BETTER

58 enrolled

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03211572 2017-07-07

OTT 17-01

82 enrolled

Breast Neoplasms

NCT01266213 2017-05-01

FLAG

147 enrolled

Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Phase 4 Unknown

800 enrolled

Triple Negative Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

600 enrolled

Breast Neoplasms

NCT01402193 2014-06-25

Study of Arimidex and Radiotherapy Sequencing

220 enrolled

Breast Neoplasms, Camurati-Engelmann Syndrome

NCT02072512 2014-02-26

PROOF

180 enrolled

Breast Neoplasms

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

396 enrolled

Breast Neoplasms

NCT01924078 2013-08-16

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

100 enrolled

Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

94 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00687648 2009-06-17

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

70 enrolled

Breast Neoplasms

NCT00902954 2009-05-15

LEANEX

540 enrolled

Breast Neoplasms

NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

2,000 enrolled